163 related articles for article (PubMed ID: 17693653)
1. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Hariharan S; Gustafson D; Holden S; McConkey D; Davis D; Morrow M; Basche M; Gore L; Zang C; O'Bryant CL; Baron A; Gallemann D; Colevas D; Eckhardt SG
Ann Oncol; 2007 Aug; 18(8):1400-7. PubMed ID: 17693653
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
Eskens FA; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom AT
Eur J Cancer; 2003 May; 39(7):917-26. PubMed ID: 12706360
[TBL] [Abstract][Full Text] [Related]
3. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
4. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
Haddad T; Qin R; Lupu R; Satele D; Eadens M; Goetz MP; Erlichman C; Molina J
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1221-1227. PubMed ID: 28477227
[TBL] [Abstract][Full Text] [Related]
6. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
[TBL] [Abstract][Full Text] [Related]
7. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
[TBL] [Abstract][Full Text] [Related]
8. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Cai W; Chen X
Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
Becker A; von Richter O; Kovar A; Scheible H; van Lier JJ; Johne A
J Clin Pharmacol; 2015 Jul; 55(7):815-24. PubMed ID: 25683324
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of continuous infusion cilengitide in patients with solid tumors.
O'Donnell PH; Undevia SD; Stadler WM; Karrison TM; Nicholas MK; Janisch L; Ratain MJ
Invest New Drugs; 2012 Apr; 30(2):604-10. PubMed ID: 20839028
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
[TBL] [Abstract][Full Text] [Related]
13. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
[TBL] [Abstract][Full Text] [Related]
14. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
[TBL] [Abstract][Full Text] [Related]
15. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
O'Donnell PH; Karovic S; Karrison TG; Janisch L; Levine MR; Harris PJ; Polite BN; Cohen EE; Fleming GF; Ratain MJ; Maitland ML
Clin Cancer Res; 2015 Nov; 21(22):5092-9. PubMed ID: 26199386
[TBL] [Abstract][Full Text] [Related]
16. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
17. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
Taga T; Suzuki A; Gonzalez-Gomez I; Gilles FH; Stins M; Shimada H; Barsky L; Weinberg KI; Laug WE
Int J Cancer; 2002 Apr; 98(5):690-7. PubMed ID: 11920637
[TBL] [Abstract][Full Text] [Related]
18. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
Gilbert MR; Kuhn J; Lamborn KR; Lieberman F; Wen PY; Mehta M; Cloughesy T; Lassman AB; Deangelis LM; Chang S; Prados M
J Neurooncol; 2012 Jan; 106(1):147-53. PubMed ID: 21739168
[TBL] [Abstract][Full Text] [Related]
19. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
20. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
